PSTX Live signaler | Maksimer profitt med Getagraph.com

KJøP 114170 min ago

@ $3.72

Utstedt: 14 feb 2024 @ 17:00

Avkastning: -22.85%

Forrige signal: feb 13 - 21:15

Forrige signal: Selg

Avkastning: 1.36 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	546 780
Gjennomsnittsvolum	766 514
Markedsverdi	276.92M
EPS	$0 ( 2024-03-14 )
Neste inntjeningsdato	( $-0.340 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.09
ATR14	$0.00700 (0.24%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Rizvi Syed Ali-aamir	Buy	250 000	Employee Stock Option (Right to Buy)
2024-04-01	Rizvi Syed Ali-aamir	Buy	185 000	Common Stock
2024-04-01	Rizvi Syed Ali-aamir	Buy	0
2024-03-01	Mylet Johanna	Buy	80 743	Common Stock
2024-03-01	Mylet Johanna	Sell	18 091	Common Stock

INSIDER POWER
88.71
Last 92 transactions
Buy: 9 056 534 \| Sell: 550 582

Volum Korrelasjon

Lang: 0.21 (neutral)

Kort: -0.51 (weak negative)

Signal:(56.223) Neutral

Poseida Therapeutics, Korrelasjon

10 Mest positive korrelasjoner
EUSGU	0.901
CVCY	0.897
AGNCM	0.884
MTRX	0.88
RING	0.879
TBNK	0.877
DOOO	0.875
VIOT	0.873
WINC	0.865
GTH	0.862

10 Mest negative korrelasjoner
PPTA	-0.858
FAIL	-0.85
AMRK	-0.842
SABRP	-0.832
HYMC	-0.827
LLNW	-0.825
PAAS	-0.812
MBCN	-0.81
GALT	-0.808
STAA	-0.805

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Poseida Therapeutics, Korrelasjon - Valuta/Råvare

-0.36
( neutral )

-0.29
( neutral )

0.00
( neutral )

0.45
( neutral )

0.22
( neutral )

Poseida Therapeutics, Økonomi

Annual	2023
Omsetning:	$64.70M
Bruttogevinst:	$64.70M (100.00 %)
EPS:	$-1.370

FY	2023
Omsetning:	$64.70M
Bruttogevinst:	$64.70M (100.00 %)
EPS:	$-1.370

FY	2022
Omsetning:	$130.36M
Bruttogevinst:	$125.19M (96.03 %)
EPS:	$-0.890

FY	2021
Omsetning:	$31 238.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.00201

Financial Reports:

No articles found.

Poseida Therapeutics,

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.